Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Media
Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyAuthor: Chris Markoch. Article Published: 5/23/2026. 
Key Points
- Kiniksa raised revenue guidance after ARCALYST sales jumped 56% year-over-year.
- The company remains the only FDA-approved treatment provider for recurrent pericarditis.
- Investors are closely watching KPL-387 as a potential next-generation growth catalyst.
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
Biopharmaceutical stocks require time and patience. But when a company gets it right, investors are rewarded, as they have been with Kiniksa Pharmaceuticals (NASDAQ: KNSA). The stock is up more than 100% over the past year. Much of that gain came after the company’s strong Q1 earnings report on April 28, when it topped adjusted earnings per share (EPS) estimates by 9 cents, coming in at 27 cents. At that time, the company also announced the launch of a targeted direct-to-consumer TV campaign for ARCALYST in recurrent pericarditis. ARCALYST is the first and only U.S. Food & Drug Administration (FDA) approved therapy for recurrent pericarditis, a designation it received in 2021.
When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early - while everyone else waits on the sidelines.
But one small infrastructure supplier - a critical piece Musk can't scale the Colossus network without - is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost. Get the SpaceX infrastructure stock name and ticker here
After some initial volatility, ARCALYST generated revenue of about $48 million in March 2023. Revenue growth has since accelerated, reaching a record $214.27 million in Q1 2026, a 56% year-over-year (YOY) increase. The new campaign is important because it shows that Kiniksa is investing in demand generation at scale rather than relying solely on prescriber growth. To that end, the company raised its full-year revenue guidance to $930 million to $945 million. The previous guidance was a range of $900 million to $920 million. A Singular Focus Moving Into Its Second GenerationLike many biotech companies, Kiniksa focuses on discovering and advancing novel, transformative therapies for patients with unmet medical needs. The company’s specific focus is on cardiovascular disease, particularly pericarditis. Pericarditis is an inflammation of the pericardium—the thin, fluid-filled sac surrounding the heart—that causes sharp chest pain, fatigue, and, in severe cases, dangerous fluid buildup around the heart. When the condition keeps returning despite standard anti-inflammatory treatments like NSAIDs and colchicine, it becomes recurrent pericarditis, a chronic autoinflammatory disease driven by an overactive IL-1 immune response. How big is this market? Approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year, with roughly 14,000 of those experiencing two or more recurrences due to persistent underlying disease or an inadequate response to conventional therapies. That 14,000 is roughly equal to Kiniksa’s initial target, of which 18% were on ARCALYST by the end of 2025. That leaves about 80% of the addressable market untreated and, for now, Kiniksa has the field to itself. The company is moving quickly to keep competitors out. That brings us to the company’s pipeline, which includes KPL-387. This is a once-monthly subcutaneous self-injection that marks a significant upgrade over ARCALYST’s more frequent dosing. KPL-387, which is in Phase 2 trials, received FDA Orphan Drug Designation (ODD) in October 2025. Among the many benefits of ODD is that Kiniksa will have exclusive marketing rights for seven years. Investors in the biotech space value exclusivity, and this gives Kiniksa another opportunity to deliver. Valuation May Become a ConcernBiotechnology stocks can be volatile, and Kiniksa is no exception. However, unlike many speculative biotech names that are unprofitable and have little to no revenue, Kiniksa has become a profitable company with revenue that is growing sequentially and YOY. That said, KNSA now trades at around 60x earnings. That’s a significant premium to the S&P 500 (around 27x) and the broader biotech sector (around 17x). The bull case is that Kiniksa has earned that premium with an outlook for strong revenue growth and higher margins. Skeptics could argue that the current stock price depends on flawless execution, which may or may not happen. However, the wait-and-see approach hasn’t worked well for investors who stayed on the sidelines, and the consensus price target of $60.86 still leaves meaningful upside from current levels. KNSA Chart Makes an Argument to WaitThe technical picture supports a measured approach for investors considering a position. After surging nearly 20% following the earnings report, KNSA has pulled back to the $53 to $54 range on declining volume. This points to a healthy consolidation, not a structural breakdown. The relative strength index (RSI) has retreated from overbought territory near 80 to a neutral 51, meaning the post-earnings momentum excess has been worked off without significant price damage. The MACD crossover, however, suggests modest near-term selling pressure may not be fully exhausted. 
Investors looking for a more defined entry point may want to watch the 50-day simple moving average, which is currently tracking in the $47 to $49 range. A successful test of that level—particularly if the MACD turns positive on the retest—would confirm that the broader uptrend remains intact and could offer a more favorable risk-reward setup ahead of the anticipated KPL-387 Phase 2 data in the second half of 2026. |
0 Response to "Dividend Income Update"
Post a Comment